Skip to content

US · AORT · MEDICAL - DEVICES

Artivion, Inc. (AORT) intrinsic value and stock valuation

$18.16as of 2026-11-21 · Mkt cap 1.27B

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Artivion, Inc. DCF and intrinsic value

InvestorsCraft values AORT with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from AORT’s statements →

Artivion, Inc. Graham Number

Graham Number: $6.92d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Kennesaw, GA 30144 artivion.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$441.3M+11.8% 5y CAGRd
20112025
Net income
$9.77M
20112025
Free cash flow
-$-910K
20112025
Total equity
$448.2M+6.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$441.3M$388.5M$354M$313.8M$298.8M
Operating income$26.8M$38.9M$5.74M$6.2M$8.12M
Net income$9.77M-$-13.36M-$-30.69M-$-19.19M-$-14.83M
EPSd$207.2K-$-320.54K-$-753.31K-$-479.39K-$-380.45K
Operating cash flow$38.1M$22.2M$18.8M-$-5.15M-$-2.58M
Capital expenditure-$-39.04M-$-11.19M-$-7.43M-$-10.71M-$-13.09M
Free cash flow-$-910K$11.1M$11.4M-$-15.87M-$-15.68M
Total assets$884.8M$789.1M$792.4M$762.8M$793.1M
Total debt$292M$362.3M$358.3M$356.8M$362M
Net debt$227.1M$308.8M$299.4M$317.5M$307M
Total equity$448.2M$276.2M$281.8M$284.3M$300.7M
Cash and short-term investments$64.9M$53.5M$58.9M$39.4M$55M
Income statement
20252024202320222021
Revenue$441.3M$388.5M$354M$313.8M$298.8M
Cost of revenue$170.9M$139.8M$124.8M$111.3M$101.3M
Gross profit$270.5M$248.8M$229.2M$202.5M$197.5M
Research and development expenses$31M$28.5M$28.7M$38.9M$35.6M
Selling, general and administrative expenses$212.7M$192.4M$209M$157.4M$169.8M
Other expenses$0.00-$-10.92M-$-14.25M$0.00-$-15.92M
Operating expenses$243.7M$209.9M$223.4M$196.3M$189.4M
Cost and expenses$414.6M$349.7M$348.3M$307.6M$290.7M
Interest income$760K$1.47M$1.08M$150K$80K
Interest expense$26.6M$34.3M$25.3M$18.2M$16.9M
Depreciation and amortization$22.5M$24.2M$23.1M$22.4M$24M
Ebitda$63.8M$51M$26.8M$25.7M$26M
Operating income$26.8M$38.9M$5.74M$6.2M$8.12M
Total other income/expenses, net-$-11.96M-$-46.39M-$-27.33M-$-21.18M-$-22.94M
Income before tax$14.8M-$-7.51M-$-21.59M-$-14.98M-$-14.83M
Income tax expense$5.01M$5.84M$9.1M$4.21M$10K
Net income$9.77M-$-13.36M-$-30.69M-$-19.19M-$-14.83M
Weighted average shares outstanding$45.3M$41.7M$40.7M$40M$39M
Weighted average diluted shares outstanding$47.2M$41.7M$40.7M$40M$39M
Balance sheet
20252024202320222021
Cash and short-term investments$64.9M$53.5M$58.9M$39.4M$55M
Net receivables$103.7M$85.9M$74.1M$69.6M$58.1M
Inventory$92.4M$79.8M$82M$74.5M$77M
Total current assets$303.6M$290.1M$280.7M$247.3M$247.7M
Property, plant and equipment, net$99.7M$76.1M$82.2M$80.5M$83.2M
Goodwill and intangible assets$410.6M$397.3M$419.6M$426.3M$451.5M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$581.3M$499M$511.7M$515.5M$545.4M
Total assets$884.8M$789.1M$792.4M$762.8M$793.1M
Accounts payable$16M$18M$13.3M$12M$10.4M
Short-term debt$5.38M$5.29M$5.43M$5.43M$5.31M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$101.6M$66.8M$57.9M$49.7M$45M
Long-term debt$286.7M$357M$352.9M$351.4M$356.7M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$335M$446.1M$452.8M$428.8M$447.4M
Capital lease obligations$37.1M$47.9M$51.4M$48.7M$52.9M
Total liabilities$436.6M$512.9M$510.6M$478.5M$492.3M
Common stock$490K$430K$430K$420K$410K
Retained earnings-$-51.5M-$-61.27M-$-47.91M-$-17.22M$1.98M
Accumulated other comprehensive income (loss)-$-2.72M-$-24.93M-$-12.01M-$-21.61M-$-9.89M
Total equity$448.2M$276.2M$281.8M$284.3M$300.7M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$292M$362.3M$358.3M$356.8M$362M
Net debt$227.1M$308.8M$299.4M$317.5M$307M
Cash flow statement
20252024202320222021
Net income$9.77M-$-13.36M-$-30.69M-$-19.19M-$-14.83M
Depreciation and amortization$22.5M$24.2M$23.1M$22.4M$24M
Stock-based compensation$24.4M$14.2M$14.4M$12.3M$10.7M
Change in working capital-$-22.16M-$-17.24M-$-16.19M-$-25.94M-$-33.23M
Accounts receivable-$-7.27M-$-15.39M-$-4.05M-$-13.34M-$-11.56M
Inventory-$-15.28M-$-6.14M-$-14.36M-$-8.4M-$-18.38M
Accounts payable$2.18M$9.5M$1.68M-$-1.96M-$-1.89M
Net cash provided by operating activities$38.1M$22.2M$18.8M-$-5.15M-$-2.58M
Investments in property, plant and equipment-$-39.04M-$-11.19M-$-7.43M-$-10.71M-$-13.09M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-42.04M-$-28.19M-$-500K-$-10.71M$5.66M
Common stock issued$13.1M$5.73M$0.00$0.00$0.00
Common stock repurchased$0.00$0.00-$-560K-$-1.79M-$-1.91M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$13M$2.2M$860K-$-1.64M-$-12.22M
Net change in cash$11.5M-$-5.48M$19.6M-$-15.66M-$-6.95M
Cash at end of period$64.9M$53.5M$58.9M$39.4M$55M
Operating cash flow$38.1M$22.2M$18.8M-$-5.15M-$-2.58M
Capital expenditure-$-39.04M-$-11.19M-$-7.43M-$-10.71M-$-13.09M
Free cash flow-$-910K$11.1M$11.4M-$-15.87M-$-15.68M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Artivion, Inc.

        Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.

        CEO
        James Patrick Mackin
        Employees
        1.8K
        Beta
        1.25

        Explore

        Frequently asked questions

        What is the intrinsic value of Artivion, Inc. (AORT)?

        Artivion, Inc. (AORT) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is AORT undervalued?

        AORT trades at a price of $18.16 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.